DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展

doi:10.6040/j.issn.1673-3770.0.2015.391

山东大学耳鼻喉眼学报 ›› 2016, Vol. 30 ›› Issue (2): 102-105.doi: 10.6040/j.issn.1673-3770.0.2015.391

DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展

李莹莹^1,2综述, 宋西成²审校

1. 滨州医学院临床医学院, 山东烟台 264003;
2. 青岛大学医学院附属烟台毓璜顶医院耳鼻咽喉头颈外科, 山东烟台 264000

收稿日期:2015-09-17 出版日期:2016-04-16 发布日期:2016-04-16
通讯作者: 宋西成. E-mail: songxicheng@126.com E-mail:liyingyingdalian@126.co
作者简介:李莹莹. E-mail: liyingyingdalian@126.co
基金资助:
山东省重点研发计划(2015GSF118090);山东省留学人员科技活动择优资助项目(鲁人社字2013-528号)

Advances on genetic polymorphism of DNA double-strand break repair genes and thyroid carcinoma.

LI Yingying^1,2, SONG Xicheng

1. Binzhou Medical University, Yantai 264000, Shandong, China;2. Department of Otolaryngology &Head and Neck Surgery, Yantai Yuhuangding Hospital, Medical College of Qingdao University, Yantai 264000, Shandong, China

Received:2015-09-17 Online:2016-04-16 Published:2016-04-16

摘要/Abstract

摘要： 未及时有效修复的DNA损伤,可导致生物体基因组不稳定,这与肿瘤发生有直接关系。DNA双链断裂DSB是基因突变、染色体断裂的主要原因之一,并对肿瘤的易感性、发生、发展具有一定影响,其修复主要是通过HR 和NHEJ 两条重组修复途径完成。综述主要目的是探讨国内外近来研究发现的两种DSB 重组修复机制中修复基因多态性与甲状腺癌易感性之间的联系。

关键词: DNA 双链断裂, 甲状腺癌, 重组修复

Abstract: Failure to repair DNA damage timely and effectively can lead to genome instability, which is directly related to the occurrence of tumor. DNA double-strand break(DSB)is the predominant cause of gene mutation and chromosome fragmentation. It affects the tumor susceptibility and process of carcinogenesis. The DSB repair depends mainly on homologous recombination(HR)and non-homologous end-joining(NHEJ). This paper aims to investigate the correlation between the DSB repair gene polymorphism and thyroid carcinoma susceptibility.

Key words: DNA double-strand break, Recombination repair, Thyroid carcinoma

中图分类号:

R736.1

李莹莹综述, 宋西成审校. DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 102-105.

LI Yingying, SONG Xicheng. Advances on genetic polymorphism of DNA double-strand break repair genes and thyroid carcinoma.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 102-105.

参考文献

[1] Siraj A K, Hussain A R, Al-Rasheed M, et al. Demethylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis[J]. J Clin Endocrinol Metab, 2011, 96(1):E215-224.
[2] Schneider D F, Chen H. New developments in the diagnosis and treatment of thyroid cancer[J]. CA Cancer J Clin, 2013, 63(6):373-394.
[3] Hundahl S A, Fleming I D, Fremgen A M, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995[J]. Cancer, 1998, 8(12):2638-2648.
[4] 钱碧云, 陈可欣, 何敏, 等. 天津市区甲状腺癌流行状况调查[J]. 中国肿瘤临床, 2005, 3294):218-221.
[5] Knauf J A, Ward L S, Nikiforov Y E, et al. Isozyme-specific abnormalities of PKC in thyroid cancer: evidence for post-transcriptional changes in PKC epsilon[J]. J Clin Endocrinol Metab, 2002, 87(5):2150-2159.
[6] Hartlerode A J, Scully R. Mechanisms of double-strand break repair in somatic mammalian cells[J]. Biochem J, 2009, 423(2):157-168.
[7] Symington L S, Gautier J. Double-strand break end resection and repair pathway choice[J]. Annu Rev Genet, 2011, 45:247-271.
[8] Shrivastav M, De Haro L P, Nickoloff J A. Regulation of DNA double-strand break repair pathway choice[J]. Cell Res, 2008, 18(1):134-147.
[9] Lieber M R, Ma Y, Pannicke U, et al. Mechanism and regulation of human non-homologous DNA end-joining[J]. Nat Rev Mol Cell Biol, 2003, 4(9):712-720.
[10] Zhang H, Hasty P, Bradley A. Targeting frequency for deletion vectors in embryonic stem cells[J]. Mol Cell Biol, 1994, 14(4):2404-2410.
[11] Burma S, Chen B P, Chen D J. Role of non-homologous end joining(NHEJ)in maintaining genomic integrity[J]. DNA Repair(Amst), 2006, 5(9-10):1042-1048.
[12] Summers K C, Shen F, Sierra Potchanant E A, et al. Phosphorylation: the molecular switch of double-strand break repair[J]. Int J Proteomics, 2011, 2011(2011):373816.
[13] Tolle R. Information technology tools for efficient SNP studies[J]. Am J Pharmacogenomics, 2001, 1(4):303-314.
[14] Sehl M E, Langer L R, Papp J C, et al. Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer[J]. Clin Cancer Res, 2009, 15(6):2192-2203.
[15] Walsh T, King M C. Ten genes for inherited breast cancer[J]. Cancer Cell, 2007, 11(2):103-105.
[16] Fornage M, Doris P A. Single-nucleotide polymorphism genotyping for disease association studies[J]. Methods Mol Med, 2005, 108:159-172.
[17] Bastos H N, Ant(~overa)o M R, Silva S N, et al. Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk[J]. Thyroid, 2009, 19(10):1067-1075.
[18] Gomes B C, Silva S N, Azevedo A P, et al. The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk[J]. Oncol Rep, 2010, 24(4):1079-1085.
[19] Kuschel B, Auranen A, McBride S, et al. Variants in DNA double-strand break repair genes and breast cancer susceptibility[J]. HumMol Genet, 2002, 11(12):1399-1407.
[20] Figueroa J D, Malats N, Rothman N, et al. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk[J]. Carcinogenesis, 2007, 28(8):1788-1793.
[21] Roddam P L, Rollinson S, ODriscoll M, et al. Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterized by aberrant class switch recombination[J]. J Med Genet, 2002, 39(12):900-905.
[22] Liu Y, Zhang H, Zhou K, et al. Tagging SNPs in nonhomologous end-joining pathway genes and risk of glioma[J]. Carcinogenesis, 2007, 28(9):1906-1913.
[23] Hayden P J, Tewari P, Morris D W, et al. Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma[J]. Hum Mol Genet, 2007, 16(24):3117-3127.
[24] Tseng R C, Hsieh F J, Shih C M, et al. Lung cancer susceptibility and prognosis associated with polymorphisms in the non-homologous end-joining pathway genes: a multiple genotype-phenotype study[J]. Cancer, 2009, 115(13):2939-2948.
[25] Sturgis E M, Zhao C, Zheng R, et al. Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis[J]. Laryngoseope, 2005, 115(6):938-945.
[26] Yuan K, Huo M, Sun Y, et al. Association between x-ray repair cross-complementing group 3(XRCC3)genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population[J]. Tumour Biol, 2015, DOI:10.1007/s13277-015-3882-4.
[27] Shen M R, Jones I M, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans[J]. Cancer Res, 1998, 58(4):604-608.
[28] Bao Y, Jiang L, Zhou J Y, et al. XRCC1 Gene Polymorphisms and the Risk of Differentiated Thyroid Carcinoma(DTC): A Meta-Analysis of Case-Control Studies[J]. PLoSOne, 2013, 8(5):e64851.
[29] Ryu R A, Tae K, Min H J, et al. XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample[J]. J Korean Med Sci, 2011, 26(8):991-995.
[30] Chiang F Y, Wu C W, Hsiao P J, et al. Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma[J]. Clin Cancer Res, 2008, 14(18):5919-5924.
[31] Zhu Q X, Bian J C, Shen Q, et al. Genetic polymorphisms in X-ray repair cross-complementing gene 1 and susceptibility to papillary thyroid carcinoma[J]. Chin J Epidemiology, 2004, 25(8):702-705.
[32] Rahimi M, Fayaz S, Fard-Esfahani A, et al. The role of Ile3434Thr XRCC7 gene polymorphism in Differentiated Thyroid Cancer risk in an Iranian population[J]. Iran Biomed J, 2012, 16(4):218-222.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展

Advances on genetic polymorphism of DNA double-strand break repair genes and thyroid carcinoma.

HTML

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 12

多维度评价

本文评价

推荐阅读 0

[1]	孙国臣,孙彦,张虹,王保为. 儿童分化型甲状腺癌的临床特征及治疗体会[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 25-28.
[2]	潘永杰,庞文会,孙国臣,孙彦,张虹. 乙酰肝素酶和D2-40在儿童甲状腺癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 29-32.
[3]	邱杰,孙莎莎,孙彦. 美国癌症联合委员会第8版甲状腺癌TNM分期解读[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 5-8.
[4]	普布次仁,刘吉峰,巴罗. 甲状腺癌与外周静脉血炎性相关指标[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 21-24.
[5]	徐书杭, 李春睿, 刘超. 儿童甲状腺癌的规范化诊治[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 12-15.
[6]	余济春. 分化型甲状腺癌颈淋巴结清扫术[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 10-12.
[7]	邱杰,孙彦. 肿瘤标志物检测在甲状腺癌临床诊治中的意义[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 28-31.
[8]	赵国伟，贺青卿，庄大勇，郑鲁明，范子义，朱见，于芳，周鹏，侯蕾，姜会平. ¹³¹I治疗分化型甲状腺癌的应用价值与风险[J]. 山东大学耳鼻喉眼学报, 2013, 27(6): 16-21.
[9]	曹磊，贺青卿，庄大勇，郑鲁明，范子义，周鹏，朱见. 选择低位小切口行甲状腺癌选择性淋巴结清扫[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 56-59.
[10]	范林军1,明佳1,黄定德2，范子义1, 赵德龙3,张毅1,杨新华1,姜军1. 腔镜甲状腺近全切除序贯131I消融治疗分化型甲状腺癌[J]. 山东大学耳鼻喉眼学报, 2011, 25(5): 11-16.
[11]	伊海金1，张宝泉2. 甲状腺癌的外科治疗分析[J]. 山东大学耳鼻喉眼学报, 2010, 24(4): 10-12.
[12]	张虎,艾琴 . 甲状腺癌再手术15例[J]. 山东大学耳鼻喉眼学报, 2007, 21(2): 166-167 .